Margaret Leesong

Margaret Leesong is the President of YidoBio Inc., a biotech company based in South Korea that specializes in developing cell therapies for diabetes and distributing related medical supplies. She has held this position since May 2017, demonstrating significant leadership in the field of biotechnology and healthcare.2

Educational Background

Margaret Leesong has an extensive educational background that includes degrees from prestigious institutions. She holds a PhD and a JD, having studied at Seoul National University and Purdue University, as well as the University of Sydney Law School.1

Professional Experience

Before her role at YidoBio, she served as a scientific advisor at SV Investment for nearly seven years. Her career reflects a strong commitment to advancing medical technology and addressing diabetes treatment through innovative research and development.2

Company Overview

YidoBio Inc., also known as Tascom, was established in 2014 and is listed on the KONEX (Korea New Exchange) stock market since 2019. The company focuses on diabetes care, collaborating with leading scientists and doctors to enhance treatment options for patients.1

Margaret Leesong's leadership is pivotal in steering the company's mission to become a prominent player in the biotechnology sector, particularly in diabetes management.